The Latest Cardiac and Vascular News
RADIANCE-HTN TRIO and SOLO trial updates demonstrate the durability of blood pressure lowering effects of the Paradise Ultrasound Renal Denervation System in a broad spectrum of patients with hypertension. PALO ALTO, Calif.–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), […]
Treatment Supported by Evidence from Multiple Studies and Renal Denervation Position Paper from the European Society of Hypertension PALO ALTO, Calif. & FRANKFURT, Germany–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today […]
PALO ALTO, Calif., March 17, 2019 /PRNewswire/ — ReCor Medical, Inc. (“ReCor”) announced the 6 month “on-medication” results from its RADIANCE-HTN SOLO clinical trial with simultaneous publication in Circulation, and the first randomization of patients in its RADIANCE-II pivotal trial of its Paradise® Renal […]
TOKYO and PALO ALTO, Calif., July 10, 2018 /PRNewswire-USNewswire/ — Otsuka Holdings Co., Ltd. (“Otsuka Holdings”), Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and ReCor Medical, Inc. (“ReCor”) announce the signing of a merger agreement pursuant to which Otsuka Holdings will acquire the remaining […]
ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In addition, the company announced submission of an IDE supplement to the US FDA for a pivotal […]
PALO ALTO, Calif., Jan. 5, 2018 /PRNewswire-USNewswire/ — ReCor Medical announced today randomization of its 146th, and final, subject in the SOLO cohort of its RADIANCE-HTN study. RADIANCE-HTN, ReCor’s study of its Paradise Renal Denervation System in people with hypertension, involves two […]
